formulation scope
SYNJARDY: metformin limits the combination product
The combination has metformin-related initiation and severe-renal restrictions. Empagliflozin monotherapy eligibility does not override them.
What to reconcileMatch both active ingredients, formulation and indication; check contrast-procedure interruption separately.
1 source identities and dates
GlobalRPh RX List - SYNJARDYGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Empagliflozin/metformin immediate-release tablets. The metformin component creates restrictions not transferable from empagliflozin alone.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
formulation scope
SYNJARDY: metformin limits the combination product
The combination has metformin-related initiation and severe-renal restrictions. Empagliflozin monotherapy eligibility does not override them.
What to reconcileMatch both active ingredients, formulation and indication; check contrast-procedure interruption separately.
1 source identities and dates
GlobalRPh RX List - SYNJARDY XRGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Empagliflozin/metformin extended-release tablets. The metformin component creates restrictions not transferable from empagliflozin alone.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
guideline difference
EMTRIVA versus NIH: explicit renal schedule deviation
The standalone capsule/solution label reduces dosing at selected bands where NIH uses no adjustment. NIH footnote b explains its incorporation of some fixed-dose-product guidance.
What to reconcileChoose and document one applicable institutional/specialist approach. Do not average schedules or silently relabel the NIH approach as the standalone product label.
2 source identities and dates
GlobalRPh RX List - EMTRIVAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult standalone EMTRIVA: capsules and 10 mg/mL oral solution have distinct renal schedules. Not automatic guidance for FTC-containing combination tablets.
Read this stored source Emtricitabine - NIH adult HIV guidanceNIH / HHS Adult and Adolescent Antiretroviral Guidelines Panel | Source revision: Source revision date not established in selected retrieval.
NIH adult/adolescent ART table; professional guidance differs from standalone EMTRIVA labeling.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
source scope
ODEFSEY: a restricted-use paragraph is not a full dialysis schedule
The selected RX renal warning describes excluded renal groups and monitoring but does not provide a complete dialysis administration instruction. Removal figures from overdose sections cannot supply that schedule.
What to reconcileUse a complete applicable product or HIV-guideline dialysis protocol; retain the RX monitoring guidance without inventing timing.
1 source identities and dates
GlobalRPh RX List - ODEFSEYGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
ODEFSEY fixed-dose HIV-treatment product; selected restrictions and renal monitoring, not a complete dialysis schedule.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
formulation scope
COMPLERA: do not transfer a component or two-drug interval
A three-drug fixed-dose TDF product cannot be adjusted by borrowing the two-drug TRUVADA interval. TAF and TDF combinations also have different renal scopes.
What to reconcileConfirm all components and use the fixed-dose product restriction; consider individually adjustable components only through an applicable full regimen.
1 source identities and dates
GlobalRPh RX List - COMPLERAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
COMPLERA fixed-dose HIV-treatment tablet, containing TDF rather than TAF.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
population scope
DESCOVY: selected adult treatment guidance is not all-population eligibility
The selected adult chronic-hemodialysis pathway does not establish a full pediatric, PrEP or boosted-protease-inhibitor regimen.
What to reconcileCheck indication, age/weight, concomitant regimen and dialysis status in the complete current product guidance.
1 source identities and dates
GlobalRPh RX List - DESCOVYGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Selected adult HIV-treatment renal eligibility for DESCOVY. This card does not reproduce a complete PrEP, pediatric or boosted-protease-inhibitor protocol.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
indication scope
TRUVADA: treatment interval reduction is not a PrEP strategy
The selected product source has different renal restrictions for treatment and prevention. Its treatment table also identifies ideal (lean) body weight.
What to reconcileConfirm indication and source-defined clearance method before selecting an interval; do not transfer the treatment-only reduced-frequency regimen to PrEP.
1 source identities and dates
GlobalRPh RX List - TRUVADAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult TRUVADA fixed-dose tablet; HIV treatment and HIV prevention have different renal restrictions.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
indication scope
BARACLUDE: the usual regimen selects the renal-table column
The 0.5 mg and 1 mg columns represent different clinical contexts. The source favors daily schedules and uses solution for small doses.
What to reconcileEstablish treatment history/liver status, then select the corresponding complete renal schedule and formulation. Do not mix the two columns.
1 source identities and dates
GlobalRPh RX List - BARACLUDEGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult entecavir: retain the usual 0.5 mg column versus the 1 mg column for lamivudine-refractory infection or decompensated liver disease.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
dialysis context
A renal infusion reduction is not a dialysis allowance
The infusion adjustment concerns low clearance in eligible adults. Dialysis dependency appears separately in the contraindications.
What to reconcileCheck dialysis status and bleeding contraindications before applying the infusion reduction. Retain bolus, duration and co-antithrombotic rules from the same protocol.
1 source identities and dates
GlobalRPh RX List - INTEGRILINGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult intravenous eptifibatide for ACS/PCI; infusion adjustment, not a complete antithrombotic order set.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.3.
guideline difference
EPZICOM: label restriction versus limited-evidence panel practice
The selected label does not recommend the fixed-dose combination below CrCl 30. NIH describes some panel members retaining full-dose lamivudine there but explicitly states that evidence is insufficient.
What to reconcilePreserve the evidence qualification and obtain HIV-specialist or institutional adjudication. Do not present that exception as a new label-approved dose.
2 source identities and dates
GlobalRPh RX List - EPZICOMGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
EPZICOM fixed-dose HIV-treatment tablet; not individually adjustable lamivudine.
Read this stored source Abacavir / lamivudine - NIH adult HIV guidanceNIH / HHS Adult and Adolescent Antiretroviral Guidelines Panel | Source revision: Source revision date not established in selected retrieval.
NIH adult/adolescent HIV treatment; explicitly qualified fixed-dose-combination exception.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
label vs institutional guidance
CrCl label bands and eviQ indexed-eGFR recommendations differ
The RX label mirror covers CrCl 15-49 with a fixed renal dose. The eviQ breast protocol uses indexed eGFR 30-50 and a percentage reduction, and describes the lower range as unstudied.
What to reconcileKeep units, indication and the complete oncology protocol together. Do not equate indexed eGFR with CrCl, silently round a percentage-derived dose, or call these recommendations identical.
2 source identities and dates
GlobalRPh RX List - HALAVENGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adults; IV eribulin mesylate for labeled oncology indications
Read this stored source eviQ breast metastatic eribulin protocoleviQ / Cancer Institute NSW | Source revision: Version 5; 5 June 2024 as-required review; kidney table as retrieved
Adult metastatic breast cancer; Australian eviQ protocol 1597
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.8.
professional protocol difference
Daily label regimen versus case-by-case post-HD institutional dosing
The label mirror uses a daily renal regimen with a timing-dependent post-HD supplement. UCSF also offers a selected post-HD-only strategy, with toxicity, age and low-weight qualifications. The source renal units and exactly-30 boundary do not align automatically.
What to reconcileUse one complete protocol with the dialysis prescription and ID/pharmacy review. Do not add the label supplement to an institutional post-HD dose or silently equate indexed and unindexed clearance.
2 source identities and dates
GlobalRPh RX List - INVANZGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult parenteral ertapenem; selected label renal/HD instructions. Pediatric renal doses are not established here.
Read this stored source UCSF adult ertapenem renal and dialysis guidanceUniversity of California San Francisco | Source revision: Source revision date not established in selected retrieval.
UCSF adult institutional ertapenem: non-dialysis, intermittent HD and continuous HD. Not universal CRRT guidance.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.3.
threshold ambiguity
Exactly six hours before HD: overlapping source wording
The label mirror says a supplement is needed within six hours but not needed when the dose is at least six hours before dialysis. The boundary is overlapping as printed.
What to reconcileClarify the timing endpoint with the controlling product label and dialysis pharmacist. Do not round an administration time to decide which instruction applies.
1 source identities and dates
GlobalRPh RX List - INVANZGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult parenteral ertapenem; selected label renal/HD instructions. Pediatric renal doses are not established here.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.3.
source scope and renal guidance
Before use: Ertugliflozin - STEGLATRO oral tablets
Do not transfer another SGLT2 product's renal eligibility or withholding interval.
What to reconcileConfirm the exact product, indication, renal measure and full source before prescribing.
1 source identities and dates
GlobalRPh RX List - STEGLATRO oral tabletsGlobalRPh-hosted RX List | Source revision: Revision not established in selected retrieval
Adults with type 2 diabetes; not a class-wide CKD or heart-failure regimen.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.3.
source scope and renal guidance
Before use: Eslicarbazepine acetate - APTIOM tablets
The 50% reduction applies to initiation, titration and maintenance, not just the final daily dose.
What to reconcileConfirm the exact product, indication, renal measure and full source before prescribing.
1 source identities and dates
GlobalRPh RX List - APTIOM tabletsGlobalRPh-hosted RX List | Source revision: 3/2019
Partial-onset seizures in patients at least 4 years old; pediatric base regimen remains weight-dependent.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.3.
dialysis scope
PARSABIV: missed dialysis is not a catch-up-dose instruction
This product is given only after hemodialysis and uses corrected calcium/PTH monitoring. Restart instructions differ after a prolonged interruption.
What to reconcileConfirm the dialysis schedule, calcium eligibility and interruption duration; use the complete hypocalcemia/titration protocol before treatment.
1 source identities and dates
GlobalRPh RX List - PARSABIVGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adults with secondary hyperparathyroidism and CKD on hemodialysis; not nondialysis CKD.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.